Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

The combination of tusamitamab ravtansine and pembrolizumab with or without chemotherapy generated responses and was well tolerated when used as first-line treatment for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.

Related Keywords

Madrid ,Spain ,Luis Paz ,Daiichi Sankyo ,Serono ,Astrazeneca ,Small Cell Lung Cancer Group ,Bristol Myers Squibb ,Oncology Department ,Novartis ,European Lung Cancer Congress ,Pfizer ,Amgen ,Alkermes ,Lung Cancer Congress ,Luis Paz Ares ,Medical Oncology Department ,Hospital Universitario ,Universidad Complutense De Madrid ,Merck Sharp ,Mirati Therapeutics ,Altum Sequencing ,Tusamitamab Ravtansine ,Pembrolizumab ,Sadc ,Antibody Drug Conjugate ,Ceacam5 ,Ceacam5 Nsclc ,Nsclc ,Non Small Cell Lung Cancer ,Lung Cancer ,Carmen Lc05 Trial ,Felcc ,D ,